

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/527,561
---------------------------	------------

<b>Filing Date</b>	<b>March 11, 2005</b>
--------------------	-----------------------

<b>First Named Inventor</b>	<b>I.E. Kopka et al.</b>
-----------------------------	--------------------------

## Group Art Unit

Examiner Name

Attorney Docket Number 21204P

1 of 4

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
W			EP 0 576 357	Sanofi	03/05/1997
			EP 0 656 354	Sanofi	06/04/1997
			WO 2004/111039	AstraZeneca AB	12/23/2004
			WO 2004/111033	AstraZeneca AB	12/23/2004
			WO 2004/111034	AstraZeneca AB	12/23/2004
			WO 2004/111038	AstraZeneca AB	12/23/2004
			WO 2005/000817	Sanofi-Aventis	01/06/2005
			WO 2004/037823	Pfizer Products Inc.	05/06/2004
			WO 2004/012671	Merck & Co., Inc.	02/12/2004
W			WO 2004/110453	Pfizer Products Inc.	12/23/2004

**Examiner  
Signature**

1/ Balasambaram

Date Considered

10/30/07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., 09/05/2003

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

**.2**

of

4

<b>Application Number</b>	<b>10/527,561</b>
---------------------------	-------------------

**March 11, 2005**

<b>First Named Inventor</b>	I.E. Kopka et al.
-----------------------------	-------------------

### Group Art Unit

**Examiner Name**

Attorney Docket Number 21204P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
W			WO 2005/020992	Solvay Pharmaceuticals GmbH	03/10/2005
			WO 2005/016286	Bristol-Myers Squibb Company	02/24/2005
			WO 2003/084943	Sanofi-Synthelabo	10/16/2003
			WO 03/027076	Solvay Pharmaceuticals B.V.	04/03/2003
			WO 2004/035566	Pfizer Products Inc.	04/29/2004
			WO 2004/094421	Pfizer Products Inc.	11/04/2004
			WO 03/051850	AstraZeneca AB/AstraZeneca UK Limited	06/26/2003
			WO 03/051851	AstraZeneca AB/AstraZeneca UK Limited	06/26/2003
			WO 2004/105699	Pharmacia Corporation	12/09/2004
W			WO 2004/018433	Glaxo Group Limited	03/04/2004

**Examiner  
Signature**

Date Considered

10/30/07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## STATEMENT BY APPLICANT

APR 29 2005

(use as many sheets as necessary)

Sheet

3

of

4

**Application Number**

10/527.561

**Filing Date**

**March 11, 2005**

**First Named Inventor**

I.E. Kopka et al.

**Group Art Unit**

**Examiner Name**

Attorney Docket Number

21204P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number  (if known)		
WJ			WO 2004/052864	Pfizer Products Inc.	06/24/2004
J			WO 98/37061	Bayer Aktiengesellschaft	08/27/1998
			WO 03/002114	AB Science	01/09/2003
			WO 03/006007	Research & Innovation Soc. Coop. A R.L.	01/23/2003
			WO 98/32441	Sanofi	07/30/1998
			WO 01/58450	Sanofi-Synthelabo	08/16/2001
			WO 2005/009479	Merck & Co., Inc.	02/03/2005
WJ			WO 03/000787	The Nisshin Oil Mills, Ltd./Ina Food Industry Co., Ltd.	03/01/2003

**Examiner  
Signature**

Date Considered

10 | 30 | 07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/06/2003

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b> (use many sheets as necessary)			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/527,561	
			Filing Date	March 11, 2005	
			First Named Inventor	I.E. Kopka et al.	
			Group Art Unit		
			Examiner Name		
Sheet	4	of	4	Attorney Docket Number	21204P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
M	AA	Le Foll et al., J. Pharm. & Exper. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"
M	AB	Lange et al., J. Med. Chem., pp. A-P, "Bioisosteric replacements of the pyrazole moiety of rimonabant ... 48(6), 1523-1539, 2005
M	AC	Piomelli et al., Trends in Pharma. Sci., Vol. 21 (2000), pp. 218-224, "The endocannabinoid system as a target for therapeutic drugs"
M	AD	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
M	AE	Xiang et al., Ann. Reports in Med. Chem., Vol. 34 (1999), pp. 199-208, "Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists"
M	AF	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
M	AG	Rinaldi-Carmona et al., Life Sciences, Vol. 56 (1995), pp. 1941-1947, "Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"
M	AH	Rinaldi-Carmona et al., FEBS Letters, Vol. 350 (1994), pp. 250-244, "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"
M	AI	Hetzheim et al., Pharmazie, Vol. 40(1) (1985), pp. 17-20, "Ringtransformation von O,N-heterocyclen"

Examiner Signature	<i>V. Balesar</i>	Date Considered	10/30/07
--------------------	-------------------	-----------------	----------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003